These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 6887873)

  • 1. Antiestrogen pharmacology and mechanism of action.
    Katzenellenbogen BS; Miller MA; Eckert RL; Sudo K
    J Steroid Biochem; 1983 Jul; 19(1A):59-68. PubMed ID: 6887873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
    Miller MA; Lippman ME; Katzenellenbogen BS
    Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions of antiestrogens with human breast cancer in long-term tissue culture.
    Lippman M; Bolan G; Huff K
    Cancer Treat Rep; 1976 Oct; 60(10):1421-9. PubMed ID: 1035504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiestrogen interaction with estrogen receptors and additional antiestrogen binding sites in human breast cancer MCF-7 cells.
    Ahn MR; Sheen YY
    Arch Pharm Res; 1997 Dec; 20(6):579-85. PubMed ID: 18982263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
    Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
    Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
    Pavlik EJ; Nelson K; Srinivasan S; Powell DE; Kenady DE; DePriest PD; Gallion HH; van Nagell JR
    Cancer Res; 1992 Aug; 52(15):4106-12. PubMed ID: 1638522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
    Murphy CS; Parker CJ; McCague R; Jordan VC
    Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological activity and receptor binding of a strongly interacting estrogen in human breast cancer cells.
    Reiner GC; Katzenellenbogen BS; Bindal RD; Katzenellenbogen JA
    Cancer Res; 1984 Jun; 44(6):2302-8. PubMed ID: 6547074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites.
    Katzenellenbogen BS; Miller MA; Mullick A; Sheen YY
    Breast Cancer Res Treat; 1985; 5(3):231-43. PubMed ID: 4027393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells.
    Reiner GC; Katzenellenbogen BS
    Cancer Res; 1986 Mar; 46(3):1124-31. PubMed ID: 3943090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.
    Watts CK; Sutherland RL
    Mol Pharmacol; 1987 May; 31(5):541-51. PubMed ID: 3553893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basic guide to the mechanisms of antiestrogen action.
    MacGregor JI; Jordan VC
    Pharmacol Rev; 1998 Jun; 50(2):151-96. PubMed ID: 9647865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
    Montano MM; Ekena K; Krueger KD; Keller AL; Katzenellenbogen BS
    Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
    Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
    Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiestrogen inhibition of prolactin-induced growth of the Nb2 rat lymphoma cell line.
    Biswas R; Vonderhaar BK
    Cancer Res; 1989 Nov; 49(22):6295-9. PubMed ID: 2804977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
    Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
    Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
    Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
    Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential inhibition of estrogen and antiestrogen binding to the estrogen receptor by diethylpyrocarbonate.
    Borgna JL; Scali J
    J Steroid Biochem; 1988 Oct; 31(4A):427-36. PubMed ID: 3050278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of the role of antiestrogen-binding sites in mediating the growth modulatory effects of antiestrogens: studies using t-butylphenoxyethyl diethylamine, a compound lacking affinity for the estrogen receptor.
    Sheen YY; Simpson DM; Katzenellenbogen BS
    Endocrinology; 1985 Aug; 117(2):561-4. PubMed ID: 4017947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biological significance of the interaction of estrogen agonists and antagonists with the estrogen receptor.
    Murphy CS; Jordan VC
    Receptor; 1990-1991 Winter; 1(1-2):65-82. PubMed ID: 2152373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.